EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische Studie

A Pragmatic Randomized Feasibility Trial of Influenza Vaccines

Niklas Dyrby Johansen, Daniel Modin, Joshua Nealon, Sandrine Samson, Camille Salamand, Matthew M Loiacono, Carsten Schade Larsen, Anne Marie Reimer Jensen, Nino Emanuel Landler, Brian L Claggett, Scott D Solomon, Martin J Landray und 8 weitere

NEJM Evidence · 24.01.2023 · 2 (2)

DOI: 10.1056/evidoa2200206 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 24.01.2023. Verfasst von Niklas Dyrby Johansen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza vaccines (QIV-HD) versus standard-dose quadrivalent influenza vaccines (QIV-SD) against hospitalizations and mortality in the general older population has not been evaluated in an individually randomized trial. Because of the large sample size required, such a trial will need to incorporate innovative, pragmatic elements. METHODS: We conducted a pragmatic, open-label, active-controlled, randomized feasibility trial in Danish citizens aged 65 to 79 years during the 2021–2022 influenza season. Participants were randomly assigned 1:1 to receive QIV-HD or QIV-SD. Randomization was integrated into routine vaccination practice, and the trial relied solely on nationwide administrative health registries for data collection. Outcomes consisted of a feasibility assessment and descriptive rVE estimates. RESULTS: We invited 34,000 persons to participate. A total of 12,477 randomly assigned participants were included in the final analyses. Mean (±SD) age was 71.7±3.9 years, and 5877 (47.1%) were women. Registry-based data collection was feasible, with complete follow-up data for 99.9% of participants. Baseline characteristics were comparable to those of the overall Danish population aged 65 to 79 years. The incidence of hospitalization for influenza or pneumonia was 10 (0.2%) of 6245 in the QIV-HD group and 28 (0.4%) of 6232 in the QIV-SD group (rVE, 64.4%; 95% confidence interval, 24.4 to 84.6). All-cause death occurred in 21 (0.3%) and 41 (0.7%) participants in the QIV-HD and QIV-SD groups, respectively (rVE, 48.9%; 95% confidence interval, 11.5 to 71.3). CONCLUSIONS: Conducting a pragmatic randomized trial of QIV-HD versus QIV-SD using existing infrastructure and registry-based data collection was feasible. The findings of lower incidence of hospitalization for influenza or pneumonia and all-cause mortality in the QIV-HD group compared with the QIV-SD group require replication in a future, fully powered trial. (Funded by Sanofi; ClinicalTrials.gov number, NCT05048589.)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanHumansFeasibility StudiesAntibodies, ViralHemagglutination Inhibition TestsVaccines, Inactivated

Substanzen

Influenza VaccinesAntibodies, ViralVaccines, Inactivated

Autor:innen und Institutionen

  • Department of Cardiology, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen.
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen.
  • School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
  • Sanofi, Lyon, France.
  • Sanofi, Swiftwater, PA.
  • Department of Clinical Medicine, Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Förderung

  • Medical Research Council

Zitieren

APA

Johansen, N. D., Modin, D., Nealon, J., Samson, S., Salamand, C., Loiacono, M. M., Larsen, C. S., Jensen, A. M. R., Landler, N. E., Claggett, B. L., Solomon, S. D., Landray, M. J., Gislason, G. H., Køber, L., Jensen, J. U. S., Sivapalan, P., Vestergaard, L. S., Valentiner-Branth, P., Krause, T. G., & Biering-Sørensen, T. (2023). A Pragmatic Randomized Feasibility Trial of Influenza Vaccines. NEJM Evidence, 2(2). https://doi.org/10.1056/evidoa2200206

Vancouver

Johansen ND, Modin D, Nealon J, Samson S, Salamand C, Loiacono MM, et al. A Pragmatic Randomized Feasibility Trial of Influenza Vaccines. NEJM Evidence. 2023;2(2). doi:10.1056/evidoa2200206

BibTeX
@article{Johansen2023,
  author = {Johansen, Niklas Dyrby and Modin, Daniel and Nealon, Joshua and Samson, Sandrine and Salamand, Camille and Loiacono, Matthew M and Larsen, Carsten Schade and Jensen, Anne Marie Reimer and Landler, Nino Emanuel and Claggett, Brian L and Solomon, Scott D and Landray, Martin J and Gislason, Gunnar H and Køber, Lars and Jensen, Jens Ulrik Stæhr and Sivapalan, Pradeesh and Vestergaard, Lasse Skafte and Valentiner-Branth, Palle and Krause, Tyra Grove and Biering-Sørensen, Tor},
  title = {A Pragmatic Randomized Feasibility Trial of Influenza Vaccines},
  journal = {NEJM Evidence},
  year = {2023},
  volume = {2},
  number = {2},
  doi = {10.1056/evidoa2200206}
}
Kostenlos starten →